RXST (RXST) financial statements
RXST reported revenue of $134M in fiscal 2025, up 55.7% a year over 5 years.
Net income was -$39M and the operating margin -35.8%, against -241.3% in 2020.
Free cash flow was -$19M.
The diluted share count rose 638% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from RXST's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $15M | $23M | $49M | $89M | $140M | $134M |
| Cost of revenue | $13M | $18M | $28M | $35M | $41M | $31M |
| Gross profit | $2M | $5M | $21M | $54M | $99M | $103M |
| Research and development | $22M | $24M | $26M | $29M | $34M | $39M |
| Selling, general and admin | $15M | $33M | $59M | $75M | $101M | $113M |
| Operating income | -$35M | -$53M | -$63M | -$50M | -$37M | -$48M |
| Interest expense | $510,000 | $4M | $5M | $3M | $21,000 | $19,000 |
| Pre-tax income | $28M | -$49M | -$67M | -$49M | -$27M | -$39M |
| Income tax | $57,000 | $8,000 | $9,000 | $20,000 | $50,000 | $66,000 |
| Net income | $28M | -$49M | -$67M | -$49M | -$27M | -$39M |
| EPS (diluted) | $0.15 | -$3.57 | -$2.41 | -$1.41 | -$0.71 | -$0.95 |
| Diluted shares | 6M | 14M | 28M | 34M | 39M | 41M |
| Gross margin | 11.6% | 20.0% | 43.5% | 60.4% | 70.7% | 76.6% |
| Operating margin | -241.3% | -233.6% | -129.2% | -56.2% | -26.3% | -35.8% |
| Net margin | 187.9% | -215.5% | -136.2% | -54.6% | -19.6% | -29.0% |
Balance sheet
Fiscal years, from RXST's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $69M | $159M | $106M | $127M | $237M | $228M |
| Receivables | $3M | $5M | $11M | $20M | $30M | $23M |
| Inventory | $8M | $8M | $15M | $17M | $22M | $32M |
| Total current assets | $82M | $176M | $135M | $168M | $294M | $287M |
| Property, plant and equipment | $13M | $11M | $10M | $11M | $12M | $13M |
| Total assets | $101M | $193M | $150M | $183M | $319M | $312M |
| Total current liabilities | $12M | $11M | $17M | $21M | $26M | $26M |
| Total liabilities | $45M | $54M | $60M | $22M | $37M | $36M |
| Shareholders' equity | -$431M | $138M | $90M | $160M | $281M | $276M |
| Net debt | -$14M | -$24M | -$12M | -$10M | -$17M | -$20M |
Cash flow
Fiscal years, from RXST's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$35M | -$45M | -$59M | -$42M | -$17M | -$16M |
| Capital spending | $3M | $2M | $2M | $5M | $5M | $4M |
| Free cash flow | -$38M | -$47M | -$61M | -$46M | -$22M | -$19M |
| Stock-based compensation | $4M | $8M | $11M | $16M | $25M | $32M |
| Free cash flow margin | -257.1% | -206.5% | -125.0% | -52.1% | -16.0% | -14.4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RXST.
Open RXST in InvestinglyQuestions
What was RXST's revenue in 2025?
$134M in fiscal 2025, from its 10-K filing.
How much free cash flow does RXST generate?
-$19M in fiscal 2025 (operating cash flow minus capital spending).
From RXST's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.